2seventy bio (NASDAQ:TSVT) Rating Increased to Outperform at Leerink Partnrs

2seventy bio (NASDAQ:TSVTGet Free Report) was upgraded by stock analysts at Leerink Partnrs from a “market perform” rating to an “outperform” rating in a note issued to investors on Wednesday, PriceTargets.com reports. Leerink Partnrs also issued estimates for 2seventy bio’s Q1 2025 earnings at $0.37 EPS, Q2 2025 earnings at $0.27 EPS, Q3 2025 earnings at $0.13 EPS, Q4 2025 earnings at $0.14 EPS and FY2028 earnings at $1.64 EPS.

Several other brokerages also recently commented on TSVT. SVB Leerink raised shares of 2seventy bio from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $5.00 to $18.00 in a research note on Wednesday. Citigroup assumed coverage on 2seventy bio in a report on Thursday, October 12th. They issued a “buy” rating and a $13.00 price objective for the company. Wedbush cut 2seventy bio from an “outperform” rating to a “neutral” rating in a research note on Monday, November 20th. Finally, TD Cowen reiterated a “market perform” rating on shares of 2seventy bio in a report on Wednesday. Five research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $13.17.

Get Our Latest Stock Report on TSVT

2seventy bio Stock Up 28.2 %

2seventy bio stock opened at $5.14 on Wednesday. The firm has a fifty day simple moving average of $3.33 and a two-hundred day simple moving average of $4.25. 2seventy bio has a twelve month low of $1.53 and a twelve month high of $15.25. The company has a market capitalization of $260.19 million, a PE ratio of -1.31 and a beta of 1.85.

2seventy bio (NASDAQ:TSVTGet Free Report) last issued its earnings results on Tuesday, November 14th. The company reported ($1.00) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.31) by $0.31. 2seventy bio had a negative net margin of 126.06% and a negative return on equity of 47.12%. The firm had revenue of $12.03 million for the quarter, compared to analysts’ expectations of $26.39 million. As a group, equities analysts expect that 2seventy bio will post -3.87 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Philip D. Gregory sold 25,613 shares of the company’s stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $3.87, for a total value of $99,122.31. Following the sale, the insider now directly owns 231,637 shares of the company’s stock, valued at $896,435.19. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, COO William D. Baird III sold 33,651 shares of 2seventy bio stock in a transaction that occurred on Wednesday, January 3rd. The shares were sold at an average price of $3.87, for a total transaction of $130,229.37. Following the completion of the transaction, the chief operating officer now directly owns 162,715 shares in the company, valued at $629,707.05. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Philip D. Gregory sold 25,613 shares of 2seventy bio stock in a transaction dated Wednesday, January 3rd. The stock was sold at an average price of $3.87, for a total value of $99,122.31. Following the completion of the transaction, the insider now directly owns 231,637 shares of the company’s stock, valued at approximately $896,435.19. The disclosure for this sale can be found here. Insiders sold a total of 135,305 shares of company stock worth $523,183 in the last quarter. 2.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On 2seventy bio

Several institutional investors and hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC lifted its stake in 2seventy bio by 20.9% during the 4th quarter. SG Americas Securities LLC now owns 27,315 shares of the company’s stock valued at $117,000 after acquiring an additional 4,715 shares during the period. Exchange Traded Concepts LLC lifted its position in 2seventy bio by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 34,616 shares of the company’s stock valued at $148,000 after purchasing an additional 8,778 shares during the period. Deutsche Bank AG grew its position in 2seventy bio by 15.7% in the 3rd quarter. Deutsche Bank AG now owns 26,134 shares of the company’s stock worth $102,000 after purchasing an additional 3,537 shares during the period. Public Employees Retirement System of Ohio grew its position in 2seventy bio by 112.6% in the 3rd quarter. Public Employees Retirement System of Ohio now owns 84,757 shares of the company’s stock worth $332,000 after purchasing an additional 44,895 shares during the period. Finally, Vanguard Group Inc. raised its stake in 2seventy bio by 7.4% during the 3rd quarter. Vanguard Group Inc. now owns 3,733,877 shares of the company’s stock valued at $14,637,000 after buying an additional 256,203 shares during the last quarter. Institutional investors own 98.49% of the company’s stock.

2seventy bio Company Profile

(Get Free Report)

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and chimeric antigen receptor-T cell product candidates for the treatment of multiple myeloma.

Read More

Analyst Recommendations for 2seventy bio (NASDAQ:TSVT)

Receive News & Ratings for 2seventy bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 2seventy bio and related companies with MarketBeat.com's FREE daily email newsletter.